Neurocognitive and pharmacological approach to specific learning disorders;Abordaje neurocognitivo y farmacologico de los trastornos especificos del aprendizaje

Revista de Neurologia

Volumn 28, Issue SUPPL. 2, 1999, Pages

  Etchepareborda, M C ^a  

^a Laboratorio para el Estudio de las Funciones Cerebrales Superiores   (Argentina)

Author keywords

Citicolina; Discalculia; Dysgraphia; Dyslexia; Methylphenidate; Neurocognitive training; Pipamperona; Priacetam; Selegilina; Specific learning disorders; Thiapride

Indexed keywords

DEHYDROCHOLIC ACID; METHYLPHENIDATE; PIPAMPERONE; PIRACETAM; SELEGILINE; TIAPRIDE; DOPAMINE; SEROTONIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; COGNITION; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DYSGRAPHIA; DYSLEXIA; HUMAN; LEARNING DISORDER; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; CHILD; COGNITIVE DEFECT; COGNITIVE THERAPY; DRUG THERAPY; HOSPITALIZATION; METABOLISM; METHODOLOGY; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REVIEW;

CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; COGNITIVE THERAPY; DOPAMINE; DRUG THERAPY; HUMANS; LEARNING DISORDERS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEVERITY OF ILLNESS INDEX;

EID: 0033395539     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. DSM-IV. Manual diagnóstico y estadístico de los trastornos mentales. Barcelona: Masson; 1995.
2. Nass R. Developmental dyslexia: an update. In Amir N, Rapin Y, Branski D, eds. Pediatric neurology behavior and cognition of the child with brain dysfunction. Basel: Karger; 1991. p. 164-74.
3. Maurer K. Topographic brain mapping of EEG and evoked potentials. Berlin: Springer-Verlag; 1989.
4. Martinius J. Cognitive correlates of abnormal EEG waveforms in children. In Rothenberger A, ed. Brain and behavior in child psychiatry. Berlin: Springer-Verlag; 1990. p. 125-31.
5. Etchepareborda MC, Etchepareborda J, González SA. Relación entre el espectro de coherencia de la actividad bioeléctrica cerebral y los hallazgos neuropsicológicos en pacientes con síndrome disatencional e hiperactividad. Rev Neural 1994; 22: 266-71.
6. Chiarenza GA. A neuropsychological approach to specific developmental learning disabilities. In Rothenberger A, ed. Brain and behavior in child psychiatry. Berlin: Springer-Verlag; 1990. p. 131-47.
7. Rezai K, Andreasen N, Alliger R, Cohen G, Swayze II V, O'Leary DS. The neuropsychology of the prefrontal cortex. Arch Neurol 1993; 50: 636-42.
8. Vendrell P, Junqué C, Pujol J, Jurado MA, Molet J, Grafman J. The role of prefrontal regions in the strop task. Neuropsychologia 1995; 33: 341-52.
9. Corbetta M, Miezin FM, Shulman GL, Petersen SE. A PET study of visuospatial attention. J Neuroscience 1993; 13: 1202-26.
10. Rothenberger A. The role of the frontal lobes in child psychiatric disorders. In Rothenberger A, ed. Brain and behavior in child psychiatry. Berlin: Springer-Verlag; 1990. p. 34-59.
11. Yordonova J, Dumais-Huber C, Rothenberger A, Woerner W. Prontocortical activity in children with comorbidity of tics disorder and attention-deficit hyperactivity disorder. Soc Biol Psychiatry 1997; 41: 585-94.
12. Conners CK. Biological approaches to classification and treatment of dyslexia. In Rothenberger A, ed. Brain and behavior in child psychiatry. Berlin: Springer-Verlag; 1990. p. 147-57.
13. Stuss DT, Benson DF. The frontal lobes. New York: Raven Press; 1986.
14. Springer SP, Deutsch G. Cerebro izquierdo, cerebro derecho. Colección Limites de la Ciencia. Barcelona: Gedisa; 1984.
15. Shalev RS, Wertman-Elad R. Developmental dyscalculia. In Amir N, Rapin Y, Branski D, eds. Pediatric neurology behavior and cognition of the child with brain dysfunction. Basel: Karger; 1991. p. 174-81.
16. Zametkin AJ. Attention-deficit disorder. Born to be hyperactive? JAMA 1995; 273: 1871-4.
17. Ellis AW, Young AW. Neuropsicología cognitiva humana. En Peña Casanova J, ed. Colección de neuropsicología, procesos cognitivos y rehabilitación. ¿Qué es la neuropsicología cognitiva? Barcelona: Masson; 1992. p. 1-27
18. Marcos Bars T. Neuropsicología clínica, más allá de la psicometría. Barcelona: Mosby-Doyma Libros; 1994.
19. Trimble M, Bolwing TG. The temporal lobes and the limbic system. Petersfield: Wrightson Biomedical Publishing; 1992.
20. Markowitsch HJ. Information processing by the brain views and hypotheses from a physiological-cognitive perspective. Toronto: Hans Huber Publishers; 1988.
21. Romano EM. La computadora en el tratamiento de los problemas de aprendizaje. Buenos Aires: Nueva Vision; 1988.
22. Shallice T, Burgess PW. Deficits in strategy application following frontal lobe damage in man. Brain 1991; 114: 727-41.
23. Robertson IH, Tegnér R, Tham K, Lo A, Nimmo-Smith I. Sustained attention training for unilateral neglect: theoretical and rehabilitation Implications. J Clin Exp Neuropsychol 1995; 17: 416-30.
24. Hooper SR, Grant Willis W. Learning disability subtyping. Neuropsychological foundations, conceptual models, and issues in clinical differentiation. New York: Springer-Verlag; 1989.
25. Propuestas de Secuencia Matemáticas. Ministerio de Educación y Ciencia. Madrid: Escuela Española; 1992.
26. Mercer CD. Dificultades de aprendizaje 2. Trastornos específicos y tratamiento. Barcelona: CEAC; 1991.
27. Silverstone T, Turner P. Drug treatment in psychiatry. 5 ed. London: Routledge; 1995.
28. Yordonova J, Dumais-Huber C, Rothenberger A. Coexistence of tics and hyperactivity in children: no additive effect at the psychophysiological level. Int J Psychophysiol 1996; 21: 121-33.
29. Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994; 33: 882-93.
30. Pelham WE, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B. Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity. Disorder in the classroom. J Consult Clin Psychol 1993; 61: 506-15.
31. Rothenberger A, Johannsen H, Schulze H, Amorosa H. Psychopharmacological treatment of stuttering in children. In Racagni G, et al, eds. Biological Psychiatry. Vol. 1. Amsterdam: Elsevier Science Publishers; 1991.
32. Drug evaluation monographs. Topic: Methylphenidate. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.
33. Gilman AG, Rall TW, Nies AS, et al. Goodman and Gilman's the pharmacological basis of therapeutics. 8 ed. New York: Pergamon Press; 1990.
34. Olin B. Facts and comparisons. St Louis: JB Lippincott; 1991.
35. Denckla MB, Bemporad JR, Mackay MC. Tics following methyphenidate administration. A report of 20 cases. JAMA 1976; 235; 1349-51.
36. Koehler Troy C, Strober M, Malenbaum R. Methylphenidate: induced mania in a prepubertal child. J Clin Psychiatry 1986; 47: 566-7.
37. Stein MA, Boldis TA, Schnitter ER, et al. methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996; 98: 748-56.
38. Brown P, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on impulsive behavior. Pediatrics 1979; 64: 408-11.
39. Barkley RA, Cunningham CE. The effect of Methylphenidate on the mother: child interactions of hyperactive children. Arch Gen Psychiatry 1976; 36: 201-8.
40. Campbell L, Malone MA, Kershner JR, et al. Methylphenidate slows right hemisphere procesing in children with attention deficit/hyperactivity disorder. Child Adolesc Psycopharmacol 1996; 6: 229-39.
41. Famularo R, Fenton T. The effect of methyilphenidate slows right hemisphere processing in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 1996; 6: 229-39.
42. Gross Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130: 670-4.
43. Van Dyck CH, McMahon TJ, Rosen MI, et al. Sustained-release methylphenidate for cognitive impairment in HIV-1 infected drug abusers: a pilot study. Neuroscience 1997; 9: 29-36.
44. Grubb BP, Kosinski D, Mouhaffel A, et al. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope. Pace 1996; 19: 836-40.
45. Whyte J, Hart T, Schuster K, et al. Effects of methylphenidate on attentional function after traumatic brain injury: a randomized, placebo-controlled trial. Am J Phys Med Rehabil 1997; 440-50.
46. Tacconi MT, Wurtman RJ. Piracetam: psychological disposition and mechanism of action. Adv Neurol 1986; 43: 675-85.
47. Klawans HL, Genovese N. Pharmacology of dementia. Neurol Clin 1986; 4: 459-67.
48. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101: 147-59.
49. Drug evaluation monographs. Topic: Piracetam. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.
50. Branconnier RJ. The efficacy of the cerebral metabolic enhancer in the treatment of senile dementia. Psycopharmacol Bull 1983; 19: 212-9.
51. Wilsher CR, Bennet D, Chase CH, et al. Piracetam and dyslexia effects on reading test. J Clin Psychopharmacol 1987; 7: 230-7.
52. Di Ianni M, Wilsher CR, Blank MS, et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol 1985; 5: 272-8.
53. Ackerman PT, Dykman RA, Hooloway C, et al. A trial of piracetam in two subgroup of students with dyslexia enrolled in summer tutoring. J Learn Disabil 1991; 24: 542-9.
54. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8: 63-8.
55. Gini EK, Sonnet J. Use of piracetam improves sickle cell deformability in vitro and in vivo. J Clin Pathol 1987; 40: 99-102.
56. Moriau M, Lavenne Pardonge E, Crasborn L, et al. Treatment of the Rayanud's phenomenon with piracetam. Arzneimittelforschung 1993; 43: 526-35.
57. Drug evaluation monographs. Topic: Citicolina. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.
58. Eberhardt R, Birbamer G, Gerstenbrand F, et al. Citicoline in the treatment of Parkinson's disease. Clin Ther 1990; 12: 489-95.
59. De la Morena E. Efficacy of CPD: choline in the treatment of senile alteration in memory. Ann NY Acad Sci 1991; 640: 233-6.
60. García-Mas A, Rossiñol A, Roca M, et al. Effects of citicholine in subcortical dementia associated with Parkinson's disease assessed by quantified. Electroencephalog Clin Ther 1992; 12: 489-95.
61. Fernández RL. Efficacy and safety of oral CDP-choline. Arzneimittelforschung 1983; 33: 1073-80.
62. Moglia A, Arrigo A, Bono G, et al. Citicoline in patients with chronic cerebrovascular disease (CCDV): quantitative EEG study. Curr Ther Res 1984; 36: 309-13.
63. Drug evaluation monographs. Topic: Tiapride. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.
64. Drug evaluation monographs. Topic: Pipamperone. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.
65. Van Hemert JCJ: Pipamperone (Dipiperon ®, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long term follow-up. Acta Psychiatr Scand 1975; 52: 237-45.
66. Drug evaluation monographs. Topic: Selegiline. Micromedex; 1998. Base de datos de Internet. Janssen-Cilag. 31.11.98.